
Inhibikase Therapeutics (IKT) Earnings Dates & Reports
Inhibikase Therapeutics (IKT) Most Recent Earnings
Report DateMay 14, 2025
Period EndingQ1 2025
Est. EPS-$0.11
Actual EPS-$0.15
EarningsMiss
Inhibikase Therapeutics (IKT) Earnings
View the latest Inhibikase Therapeutics (IKT) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Inhibikase Therapeutics (IKT)
Order type
Buy in
Order amount
Est. shares
0 shares
Inhibikase Therapeutics (IKT) Earnings per Share (EPS) History
Signup for full accessBrowse free
Inhibikase Therapeutics (IKT) Latest Earnings
The value each IKT share was expected to gain vs. the value each share gained.
Inhibikase Therapeutics (IKT) reported its most recent earnings on May 14, 2025 for Q1 2025, posting earnings per share (EPS) of -$0.15. This exceeded analysts' expectations of -$0.11 by 36.36%, marking a Miss.
For comparison, Inhibikase Therapeutics reported EPS of -$0.73 in the same quarter last year.
The company is expected to announce its next earnings report on 06/27/2025, with analysts projecting an EPS of -$0.10.
Inhibikase Therapeutics (IKT) Earnings History
Earnings | Est. EPS | Actual EPS | Surprise | |
---|---|---|---|---|
Q4 2024Mar 27, 2025 | -$0.10 | Next earnings call Jun. 27, 2025 | ||
Q1 2025May 14, 2025 | -$0.11 | -$0.15 | +36.36% | |
Q3 2024Nov 14, 2024 | -$0.67 | -$0.65 | -2.99% | |
Q2 2024Aug 15, 2024 | -$0.67 | -$0.66 | -1.49% | |
Q1 2024May 16, 2024 | -$0.79 | -$0.73 | -7.59% | |
Inhibikase Therapeutics (IKT) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Inhibikase Therapeutics’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
Report date | Price 1D before | Price 1D after | Change |
---|---|---|---|
May 14, 2025 | — | — | — |
Nov 14, 2024 | — | — | — |
Aug 14, 2024 | — | — | — |
May 15, 2024 | — | — | — |
Inhibikase Therapeutics (IKT) Earnings FAQs
Inhibikase Therapeutics (IKT) last reported earnings on May 14, 2025 for Q1 2025, posting an EPS of -$0.15, which Miss the estimate of -$0.11 by 36.36%.
For Q1 2025, Inhibikase Therapeutics (IKT) reported an EPS of -$0.15, missing analysts' estimate of -$0.11 by 36.36%.
For Q1 2025, Inhibikase Therapeutics (IKT) Miss expectations with an actual EPS of -$0.15 vs. an estimated EPS of -$0.11.
Following the last earnings report on May 14, 2025, Inhibikase Therapeutics (IKT)'s stock price moved — from — to —.
The next Inhibikase Therapeutics (IKT) earnings call is scheduled for Jun. 27, 2025, where executives will discuss financial results and outlook.